Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dichloroethane | decreases expression | EXP | | 6480464 | ethylene dichloride results in decreased expression of BCL2L13 mRNA | CTD | PMID:28960355 | 17alpha-ethynylestradiol | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of BCL2L13 mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | increases expression | EXP | | 6480464 | Ethinyl Estradiol results in increased expression of BCL2L13 mRNA | CTD | PMID:17942748 | 17beta-estradiol | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA | CTD | PMID:20823114 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2L13 mRNA | CTD | PMID:17101203 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of BCL2L13 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of BCL2L13 mRNA | CTD | PMID:17942748 | 2,4-dinitrotoluene | affects expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | 2 and 4-dinitrotoluene affects the expression of BCL2L13 mRNA | CTD | PMID:21346803 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L13 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL2L13 mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | increases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | bisphenol S results in increased expression of BCL2L13 protein | CTD | PMID:34186270 | 4-hydroxyphenyl retinamide | decreases expression | EXP | | 6480464 | Fenretinide results in decreased expression of BCL2L13 mRNA | CTD | PMID:28973697 | 5-azacytidine | increases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Azacitidine results in increased expression of BCL2L13 mRNA | CTD | PMID:20823114 | acetamide | decreases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | acetamide results in decreased expression of BCL2L13 mRNA | CTD | PMID:31881176 | all-trans-retinoic acid | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of BCL2L13 mRNA | CTD | PMID:23724009 | antimycin A | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Antimycin A results in decreased expression of BCL2L13 mRNA | CTD | PMID:33512557 | atrazine | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Atrazine results in decreased expression of BCL2L13 mRNA | CTD | PMID:22378314 | bisphenol A | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of BCL2L13 mRNA | CTD | PMID:22576693 | bisphenol A | increases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | bisphenol A results in increased expression of BCL2L13 protein | CTD | PMID:34186270 | bisphenol A | increases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of BCL2L13 mRNA | CTD | PMID:32145629 | bisphenol A | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L13 mRNA | CTD | PMID:28628672 | bisphenol A | affects expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | bisphenol A affects the expression of BCL2L13 mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of BCL2L13 mRNA | CTD | PMID:26063408 | bisphenol F | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL2L13 mRNA | CTD | PMID:28628672 | bucladesine | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA | CTD | PMID:20823114 | cannabidiol | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Cannabidiol results in decreased expression of BCL2L13 mRNA | CTD | PMID:27932991 | CGP 52608 | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to BCL2L13 gene] | CTD | PMID:28238834 | clofibrate | decreases expression | EXP | | 6480464 | Clofibrate results in decreased expression of BCL2L13 mRNA | CTD | PMID:17585979 | copper(II) sulfate | increases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of BCL2L13 mRNA | CTD | PMID:19549813 | coumarin | affects phosphorylation | ISO | BCL2L13 (Homo sapiens) | 6480464 | coumarin affects the phosphorylation of BCL2L13 protein | CTD | PMID:35688186 | cyclosporin A | increases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of BCL2L13 mRNA | CTD | PMID:33631201 | deguelin | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | deguelin results in decreased expression of BCL2L13 mRNA | CTD | PMID:33512557 | deoxynivalenol | increases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | deoxynivalenol results in increased expression of BCL2L13 mRNA | CTD | PMID:22846391 | dexamethasone | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L13 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL2L13 mRNA | CTD | PMID:28628672 | diazinon | affects expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | Diazinon affects the expression of BCL2L13 mRNA | CTD | PMID:22546817 | diazinon | increases methylation | ISO | BCL2L13 (Homo sapiens) | 6480464 | Diazinon results in increased methylation of BCL2L13 gene | CTD | PMID:22964155 | dieldrin | affects expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | Dieldrin affects the expression of BCL2L13 mRNA | CTD | PMID:22546817 | fenpyroximate | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | fenpyroximate results in decreased expression of BCL2L13 mRNA | CTD | PMID:33512557 | finasteride | increases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | Finasteride results in increased expression of BCL2L13 mRNA | CTD | PMID:24136188 | flutamide | increases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | Flutamide results in increased expression of BCL2L13 mRNA | CTD | PMID:24793618 | FR900359 | affects phosphorylation | ISO | BCL2L13 (Homo sapiens) | 6480464 | FR900359 affects the phosphorylation of BCL2L13 protein | CTD | PMID:37730182 | gentamycin | increases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | Gentamicins results in increased expression of BCL2L13 mRNA | CTD | PMID:33387578 | glycochenodeoxycholic acid | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Glycochenodeoxycholic Acid results in decreased expression of BCL2L13 protein | CTD | PMID:32439580 | hexadecanoic acid | increases phosphorylation | ISO | BCL2L13 (Homo sapiens) | 6480464 | Palmitic Acid results in increased phosphorylation of BCL2L13 protein | CTD | PMID:28073184 | indometacin | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L13 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL2L13 mRNA | CTD | PMID:28628672 | ivermectin | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Ivermectin results in decreased expression of BCL2L13 protein | CTD | PMID:32959892 | medroxyprogesterone acetate | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA | CTD | PMID:20823114 | methidathion | increases expression | EXP | | 6480464 | methidathion results in increased expression of BCL2L13 mRNA | CTD | PMID:34813904 | nickel dichloride | affects expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | nickel chloride affects the expression of BCL2L13 mRNA | CTD | PMID:22546817 | oxaliplatin | multiple interactions | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of BCL2L13 mRNA | CTD | PMID:25729387 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of BCL2L13 mRNA | CTD | PMID:17585979 | paracetamol | increases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of BCL2L13 mRNA | CTD | PMID:25704631 | paracetamol | affects expression | EXP | | 6480464 | Acetaminophen affects the expression of BCL2L13 mRNA | CTD | PMID:17562736 | perfluorooctanoic acid | increases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | perfluorooctanoic acid results in increased expression of BCL2L13 mRNA | CTD | PMID:19162173 | perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of BCL2L13 protein | CTD | PMID:37422089 | phenobarbital | affects expression | EXP | | 6480464 | Phenobarbital affects the expression of BCL2L13 mRNA | CTD | PMID:23091169 | picoxystrobin | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | picoxystrobin results in decreased expression of BCL2L13 mRNA | CTD | PMID:33512557 | pirinixic acid | multiple interactions | EXP | | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of BCL2L13 mRNA | CTD | PMID:19710929 | pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of BCL2L13 mRNA | CTD | PMID:18301758 and PMID:23811191 | propiconazole | decreases expression | EXP | | 6480464 | propiconazole results in decreased expression of BCL2L13 mRNA | CTD | PMID:21278054 | pyrimidifen | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | pyrimidifen results in decreased expression of BCL2L13 mRNA | CTD | PMID:33512557 | resveratrol | multiple interactions | ISO | BCL2L13 (Homo sapiens) | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of BCL2L13 mRNA | CTD | PMID:23557933 | rotenone | increases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | Rotenone results in increased expression of BCL2L13 mRNA | CTD | PMID:28374803 | rotenone | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Rotenone results in decreased expression of BCL2L13 mRNA | CTD | PMID:33512557 | silicon dioxide | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Silicon Dioxide results in decreased expression of BCL2L13 mRNA | CTD | PMID:25351596 | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of BCL2L13 protein | CTD | PMID:29044176 | tebufenpyrad | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | 4-chloro-N-((4-(1 and 1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in decreased expression of BCL2L13 mRNA | CTD | PMID:33512557 | tert-butyl hydroperoxide | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | tert-Butylhydroperoxide results in decreased expression of BCL2L13 mRNA | CTD | PMID:15336504 | thioacetamide | increases expression | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of BCL2L13 mRNA | CTD | PMID:34492290 | topotecan | multiple interactions | ISO | Bcl2l13 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of BCL2L13 mRNA | CTD | PMID:25729387 | trimellitic anhydride | increases expression | EXP | | 6480464 | trimellitic anhydride results in increased expression of BCL2L13 mRNA | CTD | PMID:19042947 | urethane | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Urethane results in decreased expression of BCL2L13 mRNA | CTD | PMID:28818685 | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of BCL2L13 mRNA | CTD | PMID:17292431 | zinc atom | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Zinc deficiency results in decreased expression of BCL2L13 mRNA | CTD | PMID:22171008 | zinc(0) | decreases expression | ISO | BCL2L13 (Homo sapiens) | 6480464 | Zinc deficiency results in decreased expression of BCL2L13 mRNA | CTD | PMID:22171008 | |